MX2020005208A - Muteinas de interleucina 2 (il-2) y usos de estas. - Google Patents

Muteinas de interleucina 2 (il-2) y usos de estas.

Info

Publication number
MX2020005208A
MX2020005208A MX2020005208A MX2020005208A MX2020005208A MX 2020005208 A MX2020005208 A MX 2020005208A MX 2020005208 A MX2020005208 A MX 2020005208A MX 2020005208 A MX2020005208 A MX 2020005208A MX 2020005208 A MX2020005208 A MX 2020005208A
Authority
MX
Mexico
Prior art keywords
compositions
pharmaceutically acceptable
therapeutic compound
same
muteins
Prior art date
Application number
MX2020005208A
Other languages
English (en)
Inventor
Joanne L Viney
Nathan Higginson-Scott
Jyothsna Visweswaraiah
Erik Robert Sampson
Kevin Lewis Otipoby
Original Assignee
Pandion Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/109,897 external-priority patent/US10174092B1/en
Application filed by Pandion Operations Inc filed Critical Pandion Operations Inc
Publication of MX2020005208A publication Critical patent/MX2020005208A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente solicitud proporciona muteínas de IL-2, composiciones que las comprenden, y métodos de uso de estas.
MX2020005208A 2017-12-06 2018-11-28 Muteinas de interleucina 2 (il-2) y usos de estas. MX2020005208A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762595357P 2017-12-06 2017-12-06
US201862675972P 2018-05-24 2018-05-24
US201862721644P 2018-08-23 2018-08-23
US16/109,897 US10174092B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
US16/109,875 US10174091B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
PCT/US2018/062808 WO2019112854A1 (en) 2017-12-06 2018-11-28 Il-2 muteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2020005208A true MX2020005208A (es) 2020-08-20

Family

ID=66751187

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005208A MX2020005208A (es) 2017-12-06 2018-11-28 Muteinas de interleucina 2 (il-2) y usos de estas.

Country Status (11)

Country Link
EP (1) EP3720470A4 (es)
JP (1) JP7250790B2 (es)
KR (2) KR20200097275A (es)
CN (1) CN111432831A (es)
AU (1) AU2018378078A1 (es)
BR (1) BR112020011343A2 (es)
CA (1) CA3083941A1 (es)
IL (1) IL274844A (es)
MX (1) MX2020005208A (es)
SG (1) SG11202003965VA (es)
WO (1) WO2019112854A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
WO2021034890A1 (en) * 2019-08-19 2021-02-25 Pandion Therapeutics, Inc. Targeted immunotolerance with a pd-1 agonist
CN110642934B (zh) * 2019-09-10 2022-08-23 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
WO2021076805A1 (en) 2019-10-15 2021-04-22 Moderna TX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
CN112358540A (zh) * 2020-11-03 2021-02-12 安徽环球基因科技有限公司 一种重组il2在毕赤酵母中的生产方法
TW202345889A (zh) * 2022-03-03 2023-12-01 大陸商海南先聲藥業有限公司 ＩＬ２突變體－抗體Ｆｃ嵌段融合蛋白的藥物組合物及其應用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1007907B (zh) * 1985-04-30 1990-05-09 弗·哈夫曼-拉罗彻有限公司 重组人类白细胞介素-2的提纯
WO2005007121A2 (en) * 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US9428567B2 (en) * 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
US20140170153A1 (en) * 2011-05-31 2014-06-19 Novo Nordisk A/S Il-21 epitope and il-21 ligands
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
SG10202010158TA (en) * 2014-07-21 2020-11-27 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20180133198A (ko) * 2016-05-04 2018-12-13 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
WO2018184965A1 (en) * 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
CA3064435A1 (en) * 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
WO2019112852A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance

Also Published As

Publication number Publication date
WO2019112854A1 (en) 2019-06-13
EP3720470A4 (en) 2021-09-15
CN111432831A (zh) 2020-07-17
AU2018378078A1 (en) 2020-06-18
JP2021507690A (ja) 2021-02-25
BR112020011343A2 (pt) 2020-11-17
KR20200097275A (ko) 2020-08-18
KR20240039201A (ko) 2024-03-26
IL274844A (en) 2020-07-30
SG11202003965VA (en) 2020-06-29
EP3720470A1 (en) 2020-10-14
CA3083941A1 (en) 2019-06-13
JP7250790B2 (ja) 2023-04-03

Similar Documents

Publication Publication Date Title
MX2020005208A (es) Muteinas de interleucina 2 (il-2) y usos de estas.
PH12020500241A1 (en) Cytokine conjugates for the treatment of autoimmune diseases
MX2023003395A (es) Composiciones de inoculante estables y metodos para producir las mismas.
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
PH12018501955A1 (en) Bridged bicyclic inhibitors of menin-mll and methods of use
MX2019001223A (es) Moduladores de receptores de quimioquina y usos de los mismos.
MX2020007812A (es) Moduladores del receptor de quimiocina y usos de los mismos.
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021012216A (es) Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
MX2020008107A (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos.
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
WO2020252208A3 (en) Macrophage specific engager compositions and methods of use thereof
WO2020102146A3 (en) User equipment power saving in new radio system
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
EP4241769A3 (en) Bisphosphocin gel formulations and uses thereof
MX2021005395A (es) Terapia del cáncer con células inmunitarias anti-liv1.
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
AU2019321490A8 (en) Ox40-binding polypeptides and uses thereof
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
MX2021016050A (es) Formulaciones transdermicas.
WO2019229536A3 (en) Novel benzodiazepine derivatives and uses thereof
MX2021006382A (es) Composiciones para el cuidado personal.
MX2021005171A (es) Inhibidores de cinasas reguladas por señal extracelular (erk) y usos de los mismos.